GMAB:OMXCOPGenmab A/S Analysis
Data as of 2026-08-15 - not real-time
$31.94
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Genmab A/S is priced at $31.94, and its moving averages give no clean directional read — the structure is neutral. The last 30 days have gained 12.0%. RSI sits at 73.4, which reads as overbought, and MACD momentum is bullish. Watch $27.86 as support and $31.98 as the nearer resistance level.
Multiples put this in undervalued territory: 25.1 times earnings against the sector's 29.8. Consensus targets land 21.2% above where the shares trade now. Revenue is growing at 24.9% on a 19.1% profit margin.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 27.1%, a beta of 0.76 and a maximum drawdown of 32.5%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Short, medium and long-term reads agree on buy, with conviction of 7/10.
Multiples put this in undervalued territory: 25.1 times earnings against the sector's 29.8. Consensus targets land 21.2% above where the shares trade now. Revenue is growing at 24.9% on a 19.1% profit margin.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 27.1%, a beta of 0.76 and a maximum drawdown of 32.5%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Short, medium and long-term reads agree on buy, with conviction of 7/10.
Top Market Events
Company Announcement COPENHAGEN, Denmark; June 11, 2026 – Genmab A/S Nasdaq: GMAB announced today that the Board of...Yahoo Finance1monIs Genmab A/S GMAB Stock Undervalued After Positive Epkinly DLBCL Trial Results?Seeking Alpha23dGenmab: Multiple Late-Stage Readouts AheadGenmab A/S GMAB has been underperforming this year.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 5/10
Key Factors
- RSI at 73.4 signals overbought conditions
- Trading above the 200-day average of 29.02
- MACD momentum is positive
Medium Term
1–3 yearsPositive
Model confidence: 6/10
Key Factors
- RSI at 73.4 signals overbought conditions
- P/E of 25.1 versus sector average of 29.8
- Trading above the 200-day average of 29.02
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- P/E of 25.1 versus sector average of 29.8
- Analyst targets imply +21.2% versus the current price
- Profit margin of 19.1% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth24.90%
Profit Margin19.07%
P/E Ratio25.1
ROE14.00%
ROA8.79%
Debt/Equity88.52
P/B Ratio3.2
Op. Cash Flow$891.0M
Free Cash Flow$870.6M
Industry P/E29.8
Technical Analysis
TrendNeutral
RSI73.4
Support$27.86
Resistance$31.98
MA 20$29.57
MA 50$27.90
MA 200$29.02
MACDBullish
VolumeIncreasing
Fear & Greed Index95.98
Valuation
Fair Value$42.99
Target Price$38.72
Upside/Downside21.23%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.76
Volatility27.06%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.